In patients with diabetes, are clopidogrel and ticlopidine effective for primary and secondary prevention of cardiovascular disease?

    loading  Checking for direct PDF access through Ovid

Abstract

EVIDENCE-BASED ANSWER

In patients with diabetes and cardiovascular disease (CVD), adenosine diphosphate (ADP) receptor antagonists (ticlopidine and clopidogrel) do not reduce all-cause mortality, vascular mortality, or myocardial infarction (MI) compared with placebo (SOR: B, individual RCT). In patients with diabetes and CVD or CVD risk factors, ADP receptor antagonists, alone or in combination with aspirin, do not reduce the combined risk of stroke, MI, and vascular mortality more than aspirin alone (SOR: B, individual RCTs).

Related Topics

    loading  Loading Related Articles